Benzinga · Feb 2, 2026
SX
NASDAQ · SXTC
China SXT Pharmaceuticals, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$3.63
Up+$0.44 (+11.98%)
Updated Aug 21, 2026, 7:20 PM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 157.8M
- P/E ratio
- -1.01
- Dividend yield
- 0.00%
- 52-week range
- $0.05 – $1,046.99
- Volume
- 272.67K
- Avg. volume
- 136.47K
Price performance
SXTC price history
1M range · 21 trading sessions · Daily adjusted prices
SXTC closed at $3.63 after 21 trading sessions, up 991.40% for the selected period.
- Last close
- $3.63
- Period change
- +991.40%
- Period low
- $0.05
- Period high
- $9.85
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $4.29 | $4.3949 | $3.60 | $3.63 | 272.67K |
| Aug 19, 2026 | $5.00 | $5.10 | $4.30 | $4.54 | 436.47K |
| Aug 18, 2026 | $4.79 | $5.55 | $4.20 | $5.13 | 13.23M |
| Aug 17, 2026 | $3.78 | $4.24 | $3.60 | $3.75 | 490.86K |
| Aug 14, 2026 | $4.60 | $4.86 | $3.68 | $4.33 | 16.11M |
| Aug 13, 2026 | $3.43 | $3.54 | $3.10 | $3.30 | 327.17K |
| Aug 12, 2026 | $3.32 | $3.39 | $3.11 | $3.30 | 189.78K |
| Aug 11, 2026 | $3.43 | $3.57 | $3.22 | $3.51 | 261.74K |
| Aug 10, 2026 | $3.78 | $4.23 | $3.15 | $3.59 | 370.54K |
| Aug 7, 2026 | $3.812 | $4.08 | $3.20 | $3.64 | 714.78K |
| Aug 6, 2026 | $4.40 | $4.64 | $4.216 | $4.312 | 612.31K |
| Aug 5, 2026 | $5.864 | $6.312 | $4.112 | $5.36 | 2.12M |
| Aug 4, 2026 | $6.00 | $10.40 | $5.20 | $9.848 | 2.11M |
| Aug 3, 2026 | $0.0724 | $0.104 | $0.07 | $0.0769 | 434.07M |
| Jul 31, 2026 | $0.069 | $0.069 | $0.0546 | $0.0618 | 61.3M |
| Jul 30, 2026 | $0.07 | $0.0918 | $0.0642 | $0.0731 | 540.74M |
| Jul 29, 2026 | $0.05 | $0.0564 | $0.0464 | $0.0525 | 58.64M |
| Jul 28, 2026 | $0.065 | $0.065 | $0.05 | $0.0576 | 65.37M |
| Jul 27, 2026 | $0.0652 | $0.081 | $0.061 | $0.0698 | 340.44M |
| Jul 24, 2026 | $0.2552 | $0.265 | $0.0525 | $0.0638 | 324.05M |
| Jul 23, 2026 | $0.4089 | $0.48 | $0.3073 | $0.3326 | 64.03M |
Latest SXTC news
The latest Smart Investors Daily articles mentioning SXTC.
Stock researchCompany · Overview
SXTC research
Overview
Company profile and research snapshot.
Company profile
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Feb 2, 2026
Why DarkIris Shares Are Trading Higher By Over 100%; Here Are 20 Stocks Moving Premarket
Yahoo · Jan 15, 2026
CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN
TAIZHOU, China, Jan. 15, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (“China SXT” or the “Company”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced as part of its Artificial Intelligence (AI) Insight
Yahoo · Jan 13, 2026
Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
New York, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the “Offering”) of approximately $10 million for its client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (the “Company” or “China SXT”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
